SEC Comment Letter 0000000000-24-009105 to Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: Aug. 9, 2024 · CIK: 0001029125 · Accession: 0000000000-24-009105
AI Filing Summary & Sentiment
File numbers found in text: 001-39468
Letter
August 9, 2024 Susan Horvath Chief Financial Officer, Treasurer and Secretary Panbela Therapeutics, Inc. 712 Vista Blvd, #305 Waconia, Minnesota 55387 Re:Panbela Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed March 26, 2024 File No. 001-39468 Dear Susan Horvath: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
August 9, 2024
Susan Horvath
Chief Financial Officer, Treasurer and Secretary
Panbela Therapeutics, Inc.
712 Vista Blvd, #305
Waconia, Minnesota 55387
Re:Panbela Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed March 26, 2024
File No. 001-39468
Dear Susan Horvath:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences